Resources

SPotlight Newsletter


Spotlight Newsletter

Fall Issue 2020

President's Report

COVID-19 has forced us to work in different ways in almost every aspect of our daily lives. But we have found new ways to connect, interact and learn. The 2020 Virtual Annual Meeting was an excellent example of just that.

A few weeks ago, we completed the live days of our first-ever Virtual Meeting. I have to say it was a great experience that exceeded my expectations in many ways. I was very proud being a part of this and was pleased with the way the technology functioned and particularly satisfied with the high-level scientific content. I would like to thank the Program Committee for their excellent job putting a great program together and enjoyed the bold introduction of several new elements - like the successful debates, dynamic poster presentations, and the Blast from the Past: Lightning round poster presentations.

At the core of our business we had an extremely well attended presentation and discussion about the Q&A of ICHS7B and E14. I am happy to see that non-clinical data is “back in the game” as part of the integrated risk assessment and I am looking forward to following the implementation. I encourage every relevant stakeholders/interested parties to become an active part of this discussion. I was also engaged with the sessions covering the role of safety pharmacologist in the development of macromolecules, gene-therapy, oligos etc. Modalities that for sure will be an important part of the future pharma pipeline.

Despite our inability to raise our glasses in person to celebrate our 20th anniversary I wish to extend a thank you to Peter Siegl, SPS’ first President, for joining us and sharing “how it all started”. I enjoyed the slideshow of images from the years that passed, it was a nice trip down memory lane.

Lastly, I would like to mention the great set of keynote speakers that presented this year. The presentations were all very well attended and I have received a lot of positive feedback on the excellent talk on COVID-19 by Michael Gralinsky (if you missed it, you can find it as part of our on demand content. All in all, the 2020 Virtual Annual Meeting was a great experience that was made possible only because of our supporters, volunteers and staff working behind the scenes. THANK YOU!

Please help us improve our future meetings by sharing your experience via the annual meeting survey

We look forward to continuing to serve our Members and find new ways to interact, connect and learn with you in the coming months and into 2021. While some of our activities in 2020 have been put on pause, we are investigating ways to invest in any new initiatives that we can for 2021 and continue to make progress on our strategic goals. If there are ways that we can better support you as a Member or the field of safety pharmacology, please email Krystle Correll.

Sincerely,

Tomas Mow, DVM, PhD, DSP
President, Safety Pharmacology Society


Annual Meeting News

2020 Virtual Meeting Highlights

Our first-ever SPS Online Annual Meeting Experience launched on September 14th and we are happy to report its overall success. Our online experience featured scientific sessions, plenary keynotes, Virtual Posters, dynamic poster presentations, lightning round poster competition, networking lounge, and morning-evening social get-togethers all within a single platform tailor made for our participants. We also featured a variety of technology and service providers showcasing their latest tools within the virtual Exhibit Hall.

In the weeks following (September 22-October 29) we have additional content hosted within the platform including, Continuing Education (CE) courses, attended poster times, Exhibit Hall access, and sponsored sessions. We encourage you to continue to join us each week as we share this important educational content with you.

If you have not signed up for the Meeting or CE Courses, it is not too late! You can register at any time and access to the on-demand content will continue through June 2021.

Congratulations and thank you to the 2020 Program Committee for organizing this exceptional program of sessions. Thanks also to the Continuing Education (CE) Committee for putting together six excellent Continuing Education courses. Recognition also goes to all the session and CE course chairs, speakers, exhibitors, sponsors, and the many others whose efforts made this outstanding Virtual program possible.

We hope you enjoyed your first virtual meeting experience with SPS, we worked hard to create it with you in mind. Please complete this brief survey to let us know how we did and what you would like to see in the future for SPS.


SPS Announces 2020 Publication Award Recipients

During our 2020 Virtual Annual Meeting, September 14-17, 2020, the Safety Pharmacology Society recognized the award recipients for our Translational Safety Pharmacology Publication Award and Technological Innovation Publication Award. The publications are nominated by SPS Members, reviewed by the SPS Awards Committee, and selected based on Relevance to Safety Pharmacology, Potential impact on the industry/field, Novelty of the research/uniqueness of approaches and concepts, Advancement of research understanding, Quality of data, and Clarity of writing.

TECHNOLOGICAL INNOVATION AWARD

The Technological Innovation Publication Award went to Sophie Fletcher, Helen Maddock, Rob S. James, Rob Wallis & Mayel Gharanei for their publication The cardiac work-loop technique: An in vitro model for identifying and profiling drug-induced changes in inotropy using rat papillary muscles.

TRANSLATIONAL SAFETY PHARMACOLOGY AWARD

The Translational Safety Pharmacology Publication Award went to Hamid R. Amouzadeh, Isaiah Dimery, Jonathan Werner, Gataree Ngarmchamnanrith, Michael J. Engwall, Hugo M. Vargas, Deborah Arrindell for their publication Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro.

Our sincere congratulations to each author who contributed to these publications!


SPS Junior Investigator Poster Contest Recipients

Congratulations to our First, Second and Third place winners!

Sophie Fletcher

Third Place
Poster #49
Measuring the Impact of Known Inotropes on Rat Papillary Muscles via the Force-Clamped Feedback Work-Loop


Fernando Escobar Ropero

Second Place
Poster #83
Distinction of IKr Blockers Based on Channel State Preference Using Voltage Clamp Simulations and Machine Learning


Prasad Purohit

First Place
Poster #23
Cation Chloride Cotransporter Modulation of the Seizure Phenotype in Rat Cortical MEA


2020 Volunteer Recognition


Thank You to Our 2020 Sponsors!

We wish to thank our 2020 Sponsors for their continued support of SPS through the years, especially a year as unique as this one has been. It is because of your support that we can offer our attendees the educational opportunities that you have seen during the Virtual Meeting. On behalf of the entire safety pharmacology community, we are grateful for your support and thank you to the following sponsors.


It’s Not Too Late: Register for On-Demand Meeting Content!

Missed the SPS Virtual Meeting Live week? Not a problem!

All the content from the Meeting is available on-demand! Register today and you receive instant unlimited access all our 2020 SPS Virtual Meeting Content until June 2021.

Don’t miss the best education in the field of safety pharmacology, register today!


Ongoing Virtual Activities: Through October 29

We hope that you've been enjoying your 20 Years of Progress: Safety Pharmacology Society Virtual Meeting experience so far, with more Attended Poster Times, Continuing Education Courses, and Sponsored Presentations still to come, we're not done yet.

Attended Poster Times

Join us Tuesdays for attended poster groups from 11:00 AM-12:30 PM EDT to chat live with poster authors. Login to the virtual meeting platform to participate.

Group #4 (10/13): In Vivo Methods & Models (Posters #41-48)
Group #5 (10/20): Cardiovascular Models (Posters #49-60)
Group #6 (10/27): Stem Cells, In Silico & CiPA (Posters #61-94)

Continuing Education Courses

Join us over the next six weeks and further your education every Thursday, starting at 10:00 AM EDT. Separate registration required. Login to the virtual meeting platform to watch!

Imaging Technologies in Safety and Preclinical Research (Thursday, October 15)

Safety Pharmacology of the Senses (Thursday, October 22)

Use of Artificial Intelligence (AI)/Machine Learning (ML) in Drug Development and Safety (Thursday, October 29)

Sponsored Presentations

Join us for these commercially supported educational sessions hosted by SPS Virtual Meeting Partners. Login to the virtual meeting platform to watch!

Tuesday, October 20 - 10:00 AM-11:00 AM EDT
Trending Topics from SPS Impacting Your Safety Pharmacology Programs
Hosted by Charles River

Join us this October for our very first SPS round table discussion. We are inviting all SPS attendees to participate in conversation regarding trending topics from this year's event. Our panel of scientists will be there to answer any questions you have about how these hot topics could affect your safety pharmacology programs and timelines.

  • ICH E14/S7B Q7A guidelines
  • Cell and gene therapy
  • Discovery through IND-enabling studies
  • Supporting CNS, cardiovascular, renal, and respiratory

Tuesday, October 27 - 10:00 AM-11:00 AM EDT
Reducing drug safety risk with high quality drug-drug interaction risk predictions
Hosted by Elsevier

Due the continuous growth of prescription drug use, there is increased risk for potential harmful drug–drug interactions (DDIs). Identifying DDI risk early during drug development is a key priority for pharmaceutical manufacturers and regulatory authorities. During this webinar, Julie Desrivot Quenelle and Eric Didier, both PKPD experts at Pierre Fabre will discuss ongoing work at Pierre Fabre to improve DDI predictions. Pierre Fabre and Elsevier partner on the development of a new DDI predictions solution.

Tuesday, October 27 - 12:30 PM-1:30 PM EDT
Safety Assessment of Anti-Viral Drugs
Hosted by Agilent Technologies

The ongoing COVID19 pandemic has focused attention on anti-viral drugs as a form of therapy for patients experiencing symptoms. A number of anti-virals, including Remdesevir has shown clinical benefits. It is imperative to understand the cardiac safety profile of these drugs. We will discuss the electrophysiological, contractile and structural impact of anti-virals alone or in combination with other drugs using hiPSC cardiomyocytes together with xCELLIgence Real-Time Cell Analysis System.


SPS NEWS

Congratulations 2021 Incoming Board Members!

We look forward to fulfilling the SPS Mission alongside you in 2021 and beyond.

Vice President-Elect
Marie-Luce Brodzinski-Rosseels, DVM, DSP, DABT

Treasurer-Elect
Annie G. Delaunois, DVM, PhD, DSP

Board of Directors
Matthew M. Abernathy, PhD, DSP
Ray Chui, PhD, DSP
Tracy Deats, MS, DABT
Nicola Fasdelli, BSc


SPS Collaborations and Activities

2020

  • SOT Scientific Liaison Coalition (Member since 2011)
  • JSPS Meeting Participation (March 2020 - Cancelled)
  • SOT Global Gallery and Post-doc Mixer participant (March 2020 - Cancelled)
  • ACT Webinar Co-sponsor (February 2020 & May 2020)
  • UW Madison Distance Learning Course support (Year-round)
  • Partner Organization in the EU Commission Grant: INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition (INSPIRE) (May 2019–September 2023)

Upcoming Webinars

Upcoming Meetings


SPS Member News

SPS Members' Book Publication: Drug Discovery and Evaluation: Methods in Clinical Pharmacology

SPS Members, Michael Gralinski and Franz Hock have published the second edition of "Drug Discovery and Evaluation: Methods in Clinical Pharmacology".

Congratulations to the authors!


Recent Publications of Interest

In Silico Classifiers for the Assessment of Drug Proarrhythmicity

Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry

Is there a role for the no observed adverse effect level in safety pharmacology?